Government has signed the Medicines and Related Substances Amendment Act (2008) marking the official existence of the much-anticipated SAHPRA. The body is now in preparation to officially take over operations from the Medicines Control Council (MCC). According to CEO of Pharma Dynamics, Erik Roos, SAHPRA could usher in a new and much more effective era for the local pharmaceutical sector as the MCC has struggled to cope with the volume of applications for new medicines and clinical trials. “SAHPRA’s new structure will follow a similar model to the US Food and Drug Administration (FDA) in that it will be more independent than the MCC,” said Roos. “Another benefit is that it will only be partly funded by government with approximately 70% of funds coming from industry bodies. This will not only enhance the entity’s ability to attract and retain the necessary skills and resources it requires to function optimally, but is critical to its success,” continued Roos. Based on industry figures, registering new products with the MCC took on average three to five years and can exceed seven years. The pharmaceutical sector is hopeful that the new body will streamline processes to effectively deal with the backlog of registrations and to fast-track the approval of essential medicines, which has long been overdue.